PlumX Metrics
Embed PlumX Metrics

Recommendations on current approach to gastric cancer

Clinical and Translational Oncology, ISSN: 1699-048X, Vol: 11, Issue: 8, Page: 518-525
2009
  • 8
    Citations
  • 0
    Usage
  • 17
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Article Description

The management of gastric cancer has been updated by the Grupo Español de Tratamiento de Tumores Digestivos (TTD). A multidisciplinary approach is essential in these patients including a precise diagnosis and staging and correct nutritional evaluation. For resectable disease, surgical resection remains the treatment mainstay and both perioperatory chemotherapy and postoperatory chemoradiotherapy are considered standard complementary treatments. In advanced disease chemotherapy should always be considered. There are different reference schemes (TCF, XC, ECF, EXC) and the therapeutic option has to be individualised. Recently a phase III trial has shown a signifi - cant improvement in overall survival when trastuzumab is added to cisplatin-capecitabine or cisplatin-5-fl uorouracil in patients with HER2+ advanced gastric cancer. Currently, there are several ongoing clinical trials evaluating the role of other new drugs against cellular targets. It would be desirable to incorporate biomarker studies in these trials in order to identify the best treatment for each patient.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know